FDA Adds Vision Risk Warning to Popular Obesity and Diabetes Drugs

The US Food and Drug Administration has mandated that popular GLP-1 medications, including Wegovy, Ozempic, and Mounjaro, carry new warning labels regarding a rare eye condition. These drugs may potentially increase the risk of developing non-arteritic anterior ischemic optic neuropathy, which can lead to vision loss. This regulatory update aims to inform patients and healthcare providers about critical ocular safety concerns associated with these widely used treatments.